Prior to VDZ therapy, highest expression of α4β7 was observed in B cells (34%), followed by CD8+ T cells (27%), CD3+ T cells (18%), and CD4+ T cells (20%) (Figure S1B in Supplementary Material) from IBD patients. The gene discussed is CD4; the disease is inflammatory bowel disease.